The importance of pathology in the German prostate cancer study PREFERE;Die Bedeutung der Pathologie in der deutschen Prostatakrebsstudie PREFERE

Pathologe

Volumn 34, Issue 5, 2013, Pages 449-462

  Kristiansen, G ^a   Stockle M ^b   Albers, P ^c   Schmidberger, H ^d   Martus, P ^e   Wellek, S ^d,f   Harter M ^g   Bussar Maatz, R ^h   Wiegel, T ⁱ  

^a UNIVERSITY OF BONN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF MANNHEIM   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h Deutsche Krebsgesellschaft E V   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Brachytherapy; Insignificant cancer; Prostate cancer; Risk groups; Treatment options

Indexed keywords

AGED; ARTICLE; BIOPSY; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; EARLY DIAGNOSIS; GERMANY; HUMAN; MALE; NEEDLE BIOPSY; PATHOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; WATCHFUL WAITING;

AGED; BIOPSY; BIOPSY, NEEDLE; EARLY DIAGNOSIS; GERMANY; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOISOTOPE TELETHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WATCHFUL WAITING;

EID: 84893658701     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-013-1788-8     Document Type: Article

References (27)

1. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101
2. Whitson JM, Porten SP, Carroll PR (2011) Prostate cancer: reducing overtreatment: Active surveillance in low-risk disease. Nat Rev Urol 8:124-125
3. Kristiansen G (2012) Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 60:125-141
4. Dall'Era MA, Albertsen PC, Bangma C et al (2012) Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 62:976-983
5. Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708-1717
6. Magheli A, Gonzalgo ML, Su LM et al (2011) Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: An analysis using propensity score matching. BJU Int 107:1956-1962
7. Ficarra V, Novara G, Artibani W et al (2009) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: A systematic review and cumulative analysis of comparative studies. Eur Urol 55:1037-1063
8. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61-71
9. Martin T, Wenz F, Bohmer D et al (2010) Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy. Urologe A 49:216-220
10. Wenz F, Martin T, Bohmer D et al (2010) The German S3 guideline prostate cancer: Aspects for the radiation oncologist. Strahlenther Onkol 186:531-534
11. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974
12. Kupelian PA, Elshaikh M, Reddy CA et al (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20:3376-3385
13. Potters L, Klein EA, Kattan MW et al (2004) Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71:29-33
14. Holm HH, Juul N, Pedersen JF et al (1983) Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 130:283-286
15. Salembier C, Lavagnini P, Nickers P et al (2007) Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 83:3-10
16. Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165-8169
17. Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29:3669-3676
18. Ross AE, Loeb S, Landis P et al (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810-2816
19. Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131
20. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228-1242
21. Epstein JI (2010) An update of the Gleason grading system. J Urol 183:433-440
22. Egevad L, Algaba F, Berney DM et al (2011) Interactive digital slides with heat maps: A novel method to improve the reproducibility of Gleason grading. Virchows Arch 459:175-182
23. Wolters T, Kwast TH van der, Vissers CJ et al (2010) False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol 34:35-43
24. Brimo F, Schultz L, Epstein JI (2010) The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 184:126-130
25. Bottke D, Golz R, Storkel S et al (2013) Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol 64:193-198
26. Montironi R, Lopez-Beltran A, Cheng L et al (2013) Control prostate pathology: should it be mandatory? Eur Urol 64:199-201
27. Bottke D, Kristiansen G, Golz R et al (2013) Reply from authors re: (...) Central pathology review: A must for prostate cancer studies and an option for selected patients in daily practise. Eur Urol 64:199-201